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The defining characteristic of recessive diseases is the absence of a phenotype in the heterozygous carriers. None-
theless, subtle manifestations may be detectable by new methods, such as expression profiling. Ataxia telangiectasia
(AT) is a typical recessive disease, and individual carriers cannot be reliably identified. As a group, however, carriers
of an AT disease allele have been reported to have a phenotype that distinguishes them from normal control
individuals: increased radiosensitivity and risk of cancer. We show here that the phenotype is also detectable, in
lymphoblastoid cells from AT carriers, as changes in expression level of many genes. The differences are manifested
both in baseline expression levels and in response to ionizing radiation. Our findings show that carriers of a recessive
disease may have an “expression phenotype.” In the particular case of AT, this suggests a new approach to the
identification of carriers and enhances understanding of their increased cancer risk. More generally, we demonstrate
that genomic technologies offer the opportunity to identify and study unaffected carriers, who are hundreds of
times more common than affected patients.
Ataxia telangiectasia (AT [MIM 208900]) is an auto-
somal recessive disease caused by mutations in the gene
ataxia telangiectasia mutated (ATM) on human chro-
mosome 11q22-23 (Savitsky et al. 1995). The ATM
product is a protein kinase that plays a role in DNA-
damage repair through cell cycle regulation. AT is a rare
disease, with a frequency of ∼1/40,000. However, het-
erozygous carriers are not rare; their frequency is ∼1/
100. Although the disease AT is recessive, epidemiolog-
ical studies have suggested that AT carriers, as a group,
have a shortened lifespan and an elevated risk of cancer,
especially breast cancer; cellular studies have shown in-
creased sensitivity to ionizing radiation (IR) (Swift et al.
1986, 1991; Athma et al. 1996; Broeks et al. 2000).
Some studies have estimated that AT carriers have a
fivefold increased risk of breast cancer compared with
control individuals and that they may account for
8%–18% of all patients with breast cancer in the United
States (Swift et al. 1976). These findings are controver-
sial; other studies have shown minimal-to-absent con-
tribution of heterozygous ATM mutations to risk of
breast cancer (FitzGerald et al. 1997; Chen et al. 1998).
The lack of a reliable diagnostic assay for the iden-
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tification of individual AT carriers has hampered studies
in this area. ATM is a large gene (∼150 kb), and there
are no common mutations causing AT (Wright et al.
1996), so sequence-based diagnostic methods are diffi-
cult (Concannon and Gatti 1997). Existing protein and
cell-based assays are inaccurate for the identification of
carriers and are time and labor intensive (Telatar et al.
1996). ATM mRNA levels are normal in almost all pa-
tients with AT and carriers of AT. AlthoughATMprotein
levels are significantly decreased in ∼85%of the patients,
they are decreased only in some AT carriers (Becker-
Catania et al. 2000). Thus, testing for ATM transcript
or protein levels will not allow detection of AT carriers.
The main goal of our study was to determine whether
AT carriers have a phenotype at the gene expression level
that differs from that of control individuals. This finding
would be of biological significance and might lead to
methods for identifying carriers individually.
Material and Methods
Study Subjects
Baseline expression levels.—We used Epstein-Barr
virus–transformed lymphoblastoid cell lines (Coriell Cell
Repositories) from 10 obligate AT carriers (GM08931,
GM03334, GM03382, GM03188, GM09588,
GM00736, GM02781, GM09585, GM09583, and
GM09579) and 10 control individuals (GM06995,
GM06997, GM07014, GM10832, GM10835,
GM10848, GM10849, GM10860, GM06987, and
GM07038) for our analysis. None of the subjects were
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known to be blood relatives. Reference samples used
in all hybridizations were made with RNA from six
CEPH individuals (GM06987, GM07038, GM06995,
GM06997, GM07014, and GM07042).
Expression response to IR.—In the first experiment,
lymphoblastoid cell lines from seven obligate AT car-
riers (GM09583, GM09579, GM08930, GM08931,
GM03334, GM03382, and GM03188) and six con-
trol individuals (GM10832, GM10835, GM10860,
GM10848, GM10849, and GM07057) were studied. In
the replication experiment, we studied the lympho-
blastoid cells lines from five new obligate AT carriers
(GM00736, GM02781, GM03187, GM09585, and
GM09588) and six new control individuals (GM06987,
GM07038, GM06995, GM06997, GM07014, and
GM07042). None of the study participants were known
to be blood relatives. Reference samples used in all hy-
bridizations were made with RNA from six CEPH in-
dividuals, as described above.
cDNA Microarrays
We randomly selected 2,880 cDNA clones from a se-
quence-verified cDNA clone set (ResearchGenetics). The
clones were grown in Luria broth–ampicillin as over-
night cultures. The cultures were then diluted (1:10 with
Tris-EDTA), were boiled at 95C for 3 min, and were
used as DNA templates for PCR amplifications. DNA
was amplified with 0.4 mM vector-specific primers (T3/
T7 or M13 forward and reverse), 200 mM dNTP, 2.5
mM MgCl2, 2.5 U Taq DNA polymerase (Perkin Elmer
or Promega), and 1# PCR buffer. Amplifications were
performed in 96-well plates by an initial denaturation
at 96C for 5 min, followed by 30 cycles of 94C for 30
s, 55C for 30 s, 72C for 30 s, and a final extension at
72C for 5 min. Of the amplicons in each 96-well plate,
10% were checked by gel electrophoresis. If the success
rate of amplifications was 90%, the amplicons were
precipitated with ethanol and dried; otherwise, the am-
plifications were repeated. The amplicons were recon-
stituted in 2# sodium chloride–sodium citrate (SSC),
0.01% sarkosyl for arraying onto aminoalkylsilane-
coated microscope slides (Sigma), using a pin-and-ring
arrayer model 417 (Affymetrix). The DNA samples on
the array were moistened over gentle steam and were
then UV-crosslinked for attachment onto the glass sur-
face. The glass arrays were denatured at 95C for 3 min
and were immediately placed into ice-cold ethanol. The
arrays were then dried by centrifugation at 1,268 g for
2 min. The arrays were prehybridized with 5# SSC,
0.2% SDS, and 1% BSA at 42C for 1 h.
Probe Preparation
Lymphoblastoid cells of the subjects were grown in
Roswell Park Memorial Institute (RPMI) 1640 medium
with 15% fetal bovine serum, 1% penicillin-strepto-
mycin, and 1% L-glutamine at 37C in a humidified 5%
CO2 chamber. Cells were grown to a density of ∼1 #
106/ml. They were irradiated with 3 grays (Gy) IR in a
137Cs gamma irradiator. To minimize variations caused
by culture conditions, all cells were irradiated 24 h after
the addition of fresh medium. The cells were harvested
before IR and at 2, 6, 12, and 24 h after IR. Total RNA
was extracted from cell pellets, using the RNeasy midi
kit (Qiagen).
In each reaction, total RNA was reverse transcribed
into fluorescently (Cy3 or Cy5) labeled cDNA, using the
Genisphere 3DNA expression array detection kit (Geni-
sphere). In brief, for each reaction, 10 mg total RNAwas
reverse transcribed using 50 nM oligo dT–Genisphere
capture primer, 0.5 mM dNTP, 200 U Superscript II
(Gibco BRL) in 1# first-strand Superscript II buffer at
42C for 2 h. The RNA from the DNA/RNA hybrids
was denatured with 0.07 M NaOH. The reaction was
then neutralized to pH 7.5, using Tris-HCl. Then, for
each array hybridization, 10% of the cDNAmixturewas
incubated with 2.5 ml Cy3 or Cy5 dendrimer in Ex-
presshyb (Clontech) at 55C for 30 min; 2 mg denatured
Cot1DNA (Gibco BRL) was added, and the entire mix-
ture was added to the prehybridized array for hybridi-
zation at 62C for at least 12 h. After hybridization, the
arrays were washed with 2# SSC and 0.2% SDS at 55C
for 7 min, followed by a wash with 2# SSC and another
with 0.2# SSC at room temperature for 7 min each.
The hybridization signals were read using a dual-laser
fluorescent scanner model 428 (Affymetrix).
Analysis of Replicated Microarrays
The scanned images were analyzed using Spotfinder
(TIGR). For each data point (observation), the hybrid-
ization signals from the image analysis yield values for
Cy3 (experimental) and Cy5 (reference). Signal inten-
sities for the Cy3 and the Cy5 channels were “normal-
ized”; the Cy3 measurements were multiplied by a scal-
ing factor to make the mean Cy3:Cy5 ratio for all the
spots on the slide p 1.0. (We assume that, on average,
the genes have the same expression level in the experi-
mental and the reference samples.) Spotfinder assigns a
signal intensity of zero to an observation when the signal
is less than the background. If the Cy5 value was zero,
that observation was not included in the analysis. (If
there is no signal in the pooled (reference) RNA, we
cannot use that observation). The Cy3 value was divided
by the Cy5 value, to give the expression ratio (R) for
each replicate of each gene.
We were particularly concerned to deal appropriately
with data for genes that are expressed in some individ-
uals but not in others. The Cy3 value (and R) for these
genes will be zero for some arrays. To allow us to take
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the logarithm of the R (see below), we replaced the R
values that are zero with R′, the smallest nonzero R
found for any gene on that slide.We completed the trans-
formation of the observations by calculating log2 of the
R and R′ values.
Replicates.—A number of studies emphasize the var-
iability of individual results frommicroarray studies (Lee
et al. 2000; Newton et al. 2001). In this project, there
were four replicates for each array hybridization. Our
present procedure for analysis can be used with any ex-
periment that includes three or more replicate obser-
vations. The goal is to eliminate single observations that
are aberrant for technical reasons and to retain only
observations that are valid, while avoiding the usual ar-
bitrary or subjective definition of outliers.
For some genes, individual replicate observationswere
discarded because the Cy5 value for that replicate was
zero. If fewer than three replicate observations remained,
we discarded that gene from the analysis. If all four
values remained, we found the replicate value that was
most deviant from the mean of the replicates and dis-
carded it. This trimming was not done if there were only
three valid observations. The trimming procedure tended
to discard the highest value somewhat more often
(∼57% of time) than the lowest one but was applied
equally to the data from carriers and from control in-
dividuals. Since our significance levels are based only on
the nonparametric permutation test described below, this
reduction in variance does not bias the resulting P values.
The rest of the analysis was performed with only the
remaining three observations. Thus, the final set of data
consists of logarithms of the original R values, and these
have been trimmed by discarding the most extreme rep-
licate value. For each gene, we calculated the mean of
the remaining replicate observations and used these for
further analysis. The software for performing this anal-
ysis of replicated microarray data is available on the
authors’ Web site, Gene Expression Profiling of Carriers
of the ATM Mutation.
Baseline Experiment
In view of the problems of multiple testing and cor-
relations among observations, we did not use any para-
metric tests of significance. We chose the t statistic, be-
cause of its familiar properties, and used it solely as a
measure of the difference between carriers and control
individuals in gene expression levels, not for a t test
(Callow et al. 2000; Tusher et al. 2001). To determine
whether there were more differences between carriers
and control individuals than would be expected by
chance, we used a permutation test (Manly 1997) as
follows: We randomly assigned each individual to one
of two groups of 10 (corresponding to the real sample
sizes); we then calculated the t score (absolute value) for
each gene. After repeating this procedure 3,000 times,
we had a distribution of t scores for each gene, which
was based on the 20 values actually observed for ex-
pression level but with group membership randomly
assigned.
For each gene, we determined whether the t score (ab-
solute value) from the real data fell among the largest
1% of values resulting from permutation. When several
t scores among the 3,000 had the same value, we as-
signed the percentile of the real value (conservatively) as
the least extreme in the set. Among the 2,880 genes/ESTs
on the array, there were 71 whose t scores fell in the
largest 1% obtained from permutation. Similarly, we
used the 3,000 sets of permutations to provide 3,000
estimates for the number of extreme t scores expected
under the null hypothesis that no genes differ in ex-
pression level between carriers and control individuals.
The frequency of permutations in which this number
was 71 (14/3,000 in our data) is our estimate of the
significance level for rejecting the null hypothesis. The
procedure used is similar to that of Storey and Tibshirani
(see “Electronic Database Information” section).
Conventional stepwise linear discriminant analysis
(SPSS) was performed with data from the 12 genes with
observations on all 20 individuals, and it identified the
four genes named in the “Classification of AT Carriers
and Control Individuals” subsection below. Adding
genes beyond the four selected did not yield discrimi-
nation that was significantly better ( ). AssignmentP ! .05
to the two groups was performed with the “leave-one-
out” cross-validation procedure.
IR Response (Time-Course) Experiment
Standardization over experiments was performed as
follows: For each time point, the set of observations for
all genes was considered separately for carriers (pooled
RNA) and control individuals (pooled RNA). Most of
the cell lines for the IR response experiment were from
individuals used previously in the baseline experiment.
The mean and standard deviation were determined (for
that time point), and each observation was expressed as
units of standard deviation from the mean for all genes.
Discriminant analysis was performed, using the sta-
tistical package SPSS, on the standardized expression
ratio(s) for only those genes that had valid observations
at all the time points. The variables are the expression
levels at five time points after IR. These were measured
on the 2,880 genes (“members” of the carrier group) in
one RNA sample pooled from carriers. The same five
variables were measured on 2,880 genes (the “members”
of the control group) in pooled RNA from control in-
dividuals. Thus, the carrier and control groups consist
of gene expression observations on the same set of genes
but in different pools of RNA. The discriminant function
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was estimated using the pooled covariance matrix for
carriers and control individuals. The discriminant score
(linear combination of five observations) for each gene
in each group was used to assign a gene expression pat-
tern to one of the two groups (with cross-validation).
For each gene, two expression patterns were assigned,
one with the observations from carriers, one with those
from control individuals. This approach detects the genes
with the most different levels of expression after IR but
does not directly address differences in time trends.
In the first experiment, this procedure resulted in 442
genes correctly assigned for both groups; in the repli-
cation experiment, this resulted in 183 (of the 442) genes
correctly assigned for both groups. To identify particular
genes with the most distinctive expression patterns, we
compared the discriminant scores for assigning each
gene to the carrier or the control group. Genes were
ranked by the difference in these two scores. This was
done for the first and the replication experiments, and
the mean of the two values was found. The genes with
largest mean difference are taken to be those with most
distinctive expression patterns.
Real-Time Quantitative RT-PCR
Five of the 183 genes that were correctly assigned in
the time-course experiments were assayed using real-
time quantitative RT-PCR. Sequences of these geneswere
obtained from UCSC Genome Browser. Primers were
designed using Primer Express software (Applied Bio-
systems). The reactions were performed with 1# SYBR-
Green PCR master mix buffer (Applied Biosystems),
300-nM forward and reverse primers, and cDNA. cDNA
from lymphoblastoid cell lines from two AT carriers
(GM09585 and GM09588) and two control individuals
(GM06987 and GM06997) was analyzed. Assays were
performed in triplicate, using an ABI 7000 instrument.
The fold change was calculated using a standard curve
analysis and was normalized to the level of b-actin. For
each gene, the data from the two AT carriers were av-
eraged, as were those from the two control individuals.
These results from RT-PCR were compared with the cor-
responding microarray results by calculating the corre-
lation coefficient of the expression ratio over the five
time points.
Results
Baseline Expression Differences
We used cDNA microarrays to compare the expres-
sion levels of genes in lymphoblastoid cells from 10 AT
carriers and 10 control individuals. The Cy3-labeled
cDNA from each individual was cohybridized with
the Cy5 reference cDNA onto microarrays containing
∼3,000 human known genes/ESTs. All hybridizations
were done with four replicates. We removed the most
deviant observation from every set of four replicates and
represented the expression level of each gene by the av-
erage of the three remaining measurements (see “Anal-
ysis of Replicated Microarrays” in the “Material and
Methods” section).
In this “baseline” experiment, we used the t statistic
to compare the expression level of each gene in cells
from AT carriers and control individuals. Our goal was
to show that there are statistically significant differences
between carriers and control individuals in the number
of genes that differ in expression level, and to identify
the genes that are most likely to show consistent differ-
ences. The large number of genes/ESTs resulted in a se-
vere multiple-testing problem, and the possible corre-
lations between genes posed an additional problem, so
we did not perform standard t tests. Instead, we assessed
the significance of the t scores for each gene empirically
by a permutation test. Among the 2,880 cDNA clones
on the arrays, we found 71 clones whose t scores ranked
in the top 1% of the 3,000 random permutations we
performed with the data from the 10 AT carriers and
10 control individuals; the absolute values of these t
scores were 1.6–5.1. Because of the large number of
tests, the corresponding P values .01 are “nominal”;
nevertheless, the true significance of the number of genes
(71 clones) can be assessed, as described below.
To determine the statistical significance of our overall
result, we used the permutations described above. These
provided 3,000 estimates of the number of genes that
have nominal by chance—that is, under the nullP  .01
hypothesis that no gene among the 2,880 differs signif-
icantly between carriers and control individuals. Among
the 3,000 permutations, we found only 14 (0.47%),with
71 clones, that met this criterion. The mean number
of genes from the permutations was 27.4. We conclude
that there are significantly ( ) more genes thatP  .005
differ in baseline expression level than would be ex-
pected under the null hypothesis.
Among the 71 clones, 29 are known genes (WEE1 is
represented by two clones), and 41 are ESTs. We list the
29 known genes (represented by 30 cDNA clones) in table
1. Among them, 15 genes (HDAC1, MAPKAP3, WEE1,
LIM, CDKN2D, THBS1, SSI2, TSSC6, CCNE1, CHN2,
G6PD, TXN2, RPA1, GCP3, and DIO1) regulate cell
growth and maintenance through various pathways, in-
cluding cell cycle control and regulation of apoptosis
(Heald et al. 1993; Liu and Weaver 1993; McLaughlin
et al. 1996; Roberts 1996; Minamoto et al. 1997; Ueno
et al. 1999; Ashburner 2000; Juan et al. 2000; Tuttle et
al. 2000). Table 1 shows the t score and the P value for
each known gene. The complete list of 71 cDNA clones,
including known genes and ESTs is available at the Gene
Expression Profiling of Carriers of the ATM Mutation
Web site, under “Baseline Experiment.” Themostmarked
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Table 1
The 30 cDNA Clones (Representing 29 Known Genes) with the Largest Difference (Nominal , byP ! .01
Permutation Test) in Baseline Expression Level between AT Carriers and Control Individuals
Gene
Symbol Gene Name df
t Score
(Carrier vs. Control) P
CSF2RA Colony-stimulating factor 2 receptor alpha 9 2.85 !.0003
HDAC1 Histone deacetylase 1 12 3.30 !.0003
MAPKAPK3 Mitogen-activated protein kinase–activated protein kinase 3 14 3.04 !.0003
SLC25A6 Solute carrier family 25, member 6 18 3.61 !.0003
WEE1 WEE1 18 3.37 .0003
TFRC Transferrin receptor (p90) 18 3.15 .0007
LIM LIM protein 18 3.81 .0010
OGT O-linked N-acetylglucosamine transferase 15 2.18 .0010
WEE1 WEE1 16 3.20 .0010
CDKN2D Cyclin-dependent kinase inhibitor 2D (p19) 18 3.31 .0013
THBS1 Thrombospondin 1 17 3.57 .0013
SSI2 STAT induced STAT inhibitor 16 3.77 .0023
TSSC6 Pan-hematopoietic expression 14 3.76 .0023
CCNE1 Cyclin E1 13 2.57 .0027
CHN2 Chimerin 18 3.14 .0030
G6PD Glucose-6-phosphate dehydrogenase 17 3.80 .0033
PLOD3 Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3 17 3.27 .0033
TXN2 Thioredoxin 16 3.27 .0037
ARF6 ADP-ribosylation factor 6 18 2.98 .0047
CSF3R Colony stimulating factor 3 receptor 16 2.14 .0047
NDST1 N-deacetylase 1 15 3.22 .0047
GOSR2 Golgi SNAP receptor complex member 2 13 3.00 .0053
KIAA0204 Ste20-related serine/threonine kinase 11 2.35 .0057
RPA1 Replication protein A1 17 2.19 .0060
GCP3 Spindle pole body protein 3 16 1.98 .0067
SULT1C1 Sulfotransferase family, 1C, member 1 13 3.04 .0073
HNRPD Heterogeneous nuclear ribonucleoprotein D 15 3.27 .0080
DIO1 Death inducer-obliterator 1 12 2.86 .0083
SLC7A6 Solute carrier family 7, member 6 7 3.01 .0083
PPP1R2 Protein phosphatase 1, regulatory subunit 2 17 2.97 .0097
NOTE.—Genes are ranked by P value.
excess of small permutation P values occurs for the 22
clones with (see list of 71 cDNA clones at theP ! .0017
authors’ Web site, under “Baseline Experiment”). This
observation suggests that these genes and ESTs are the
most likely to be “true positives.”
Classification of AT Carriers and Control Individuals
To explore the biological differences between AT car-
riers and control individuals, we wanted to identify the
largest set of genes that differ in expression between the
two groups. However, for classification purposes, we
want to have the smallest set of genes whose expression
levels, when combined in a discriminant procedure,
would yield highly accurate classification. To find that
set, we performed discriminant analysis with a subset of
the 71 clones with a nominal . In the analysis,P  .01
we used the 12 genes/ESTs for which we have expression
values in all 20 individuals. By stepwise discriminant anal-
ysis, we selected four genes (LIM, CDKN2D, TFRC, and
ARF6) and determined the best linear discriminant func-
tion. The discriminant scores for the 10 AT carriers and
10 control individuals are shown in figure 1. The ap-
parent greater variance in carriers is not surprising, in
view of the known heterogeneity of ATmutations. How-
ever, the two distributions do not overlap, so the dis-
criminant function provides highly accurate assignment
of these 20 individuals to the two groups. We also as-
sessed how accurately we would classify individuals who
were not part of the “training” sample. For this purpose,
we performed “cross-validation”; the individual to be
assigned was left out of both the selection of genes and
the calculation of the discriminant function and then
was assigned on the basis of the data from the other
19 individuals. With this more stringent requirement,
we were able to classify 95% of the 20 individuals cor-
rectly. Of the 20 cross-validation “trials,” 9 resulted in
exactly the same set of four genes as were reported in
the complete data. Of the other 11, LIM was included
in 5, CDKN2D in 9, TFRC in 10, and ARF6 in 6 trials.
These findings indicate the tendency for the four genes
to be selected even in cross-validation.
Since the 12 genes/ESTs in the starting set were se-
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Figure 1 Discriminant scores for gene expression levels in cells
from 10 AT carriers and 10 control individuals. Four genes (LIM,
CDKN2, TFRC, and ARF6) were selected by stepwise linear discri-
minant analysis. (Some points overlap with others in the plot and
cannot be distinguished.)
lected from those with the largest t scores, the high level
of accurate classification for these 20 individuals is not
surprising. Our purpose was not to show that classifi-
cation is possible but to confirm that it can be achieved
with a small number of genes and ESTs.
Differences in Transcriptional Response to IR
In view of the increased sensitivity to IR among pa-
tients with AT, we also studied the changes in expression
profiles of AT carriers in response to IR. Lymphoblastoid
cells from AT carriers and control individuals were ex-
posed to low-dose IR (3 Gy). In the “baseline” experi-
ment above, we tested expression profiles of individuals.
To reduce the number of hybridizations in this time-
course experiment, we used pooled RNA samples in-
stead of samples from individuals. This allowed us to
obtain expression profiles at five time points (instead of
at one time point, as in the previous experiment) and
nevertheless to continue our rigorous quality control by
performing four replications of all array hybridizations.
Lymphoblastoid cells from seven AT carriers and six
control individuals were studied. Cells were harvested
immediately before IR, and at 2, 6, 12, and 24 h after
IR (3 Gy). At each time, total RNA was extracted from
the cells and assembled into two pools, one from AT
carriers and the other from control individuals. Each
pooled RNA sample was reverse-transcribed, with Cy3
fluorescent tags, into labeled cDNA. The Cy3-labeled
AT carrier cDNA and the Cy3-labeled control cDNA
were separately hybridized with a common Cy5-labeled
reference cDNA onto microarrays containing ∼3,000
human genes/ESTs. Thus, there were two kinds of hy-
bridization (AT carriers and control individuals) for each
of the five time points. All the hybridizations were car-
ried out with four replicates. The replicatemeasurements
were treated, as described in the “Baseline Expression
Differences” subsection, by removing the most deviant
observations and performing the analysis on the re-
maining three measurements.
Our goal was to identify the genes that differ most
between AT carriers and control individuals in expres-
sion levels at several time points after IR. This is done
to reveal the biological differences between AT carriers
and control individuals, not for classification purposes.
The discriminant-analysis procedure allows us to replace
the set of five observations on each gene by a single
discriminant score; this score is used to assign the ex-
pression pattern of a gene to the carrier or the control
group. Under our null hypothesis, we expect only ran-
dom differences between the expression patterns of a
gene tested in the two cell types. Thus, when tested in
AT carriers, the expression pattern of a gene would have
a 50% chance of being correctly assigned as carrier;
when the same gene is tested in cells, the expression
pattern again would have a 50% chance of being cor-
rectly assigned as normal. The random chance of correct
assignment of the expression pattern in both cases to-
gether is 25%.
We analyzed only genes that gave three or four “valid”
replicate observations at all five time points in both cell
types. In the first experiment, 1,382 cDNA clones met
this criterion. Among these, the discriminant score (with
cross-validation) correctly assigned 442 clones (32%) in
both the AT carriers and control individuals; this is sig-
nificantly higher than the 346 clones (25%) expected
( ; ).2x p 36 P K .001
To follow up these results, we performed a replication
experiment with only the 442 clones identified in the
first experiment; we studied pools of RNA from five new
AT carriers and six new control individuals. Among the
442 clones, there were 377 with valid observations (at
least three replicates) at five time points in both cell
types. Among these 377 clones, 183 (48.5%) were as-
signed correctly in both groups, significantly more than
the 94 clones (25%) expected under the null hypothesis
( ; ). Thus, the expression differences2x p 111 P K .001
between carriers and control cells resulted in correct clas-
sification of approximately twice as many genes as ex-
pected by chance.
Thus, by two successive rounds of classifications, we
identified 183 clones whose expression levels in AT car-
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Figure 2 Time course of gene expression after exposure to IR
(3 Gy). Expression levels were determined in pooled RNA from lym-
phoblastoid cells from seven carriers and from six control individuals.
riers over five time points after IR are different from the
levels in control individuals. Among these 183 cDNA
clones, there were 101 uncharacterized ESTs and 82
known genes. When the 82 known genes were grouped
into Gene Ontology categories (Ashburner et al. 2000),
the two largest categories were cell growth and main-
tenance (25 genes; e.g., B-cell lymphoma 3 [BCL3],
exportin 1 [XPO1], and cell growth regulator 19
[CGR19]) and signal transduction (15 genes; e.g., in-
terferon receptor a2, jagged 2, IkB kinase complex–
associated protein). Compared with the proportions of
genes in these categories present on the array (11% in
cell growth and maintenance, 13% in signal transduc-
tion), the proportions observed are higher ( ) forP ! .001
cell growth and maintenance. For illustration, we show
the expression profiles of three genes (BCL3, XPO1, and
CGR19) from the cell growth and maintenance category
(fig. 2).
We expected some correct classification by chance
(false positives). We ranked the 183 genes by the dif-
ferences in discriminant scores between AT carriers and
control individuals in the first and the replication studies.
The top-ranked genes are most likely to be true positives.
Among the 183 genes, the 10 known genes with the
largest differences in discriminant scores between AT
carriers and control individuals are listed in order in
table 2. The complete ranked list of 183 genes/ESTs is
available at the authors’ Web site under “IR responses.”
Independent confirmation of the microarray results
was obtained by quantitative RT-PCR for 5 of the 183
genes: BCL3, CCN1, CHEK1, COL15A1, and DAPK.
For each gene, we calculated the correlation coefficient
for the corresponding observations from microarrays
and RT-PCR on cDNA from carriers and from control
individuals. There was good agreement between the data
from microarray and RT-PCR analysis. The average of
the correlation coefficient was 0.76, with a range of
0.63–0.95.
Discussion
Autosomal recessive diseases that result from single
mutations can have many, apparently unrelated, man-
ifestations (pleiotropy). However, there is usually no
marked heterozygote phenotype that permits identifi-
cation of individual heterozygous carriers of a recessive
disease. Patients with AT, who have mutations in both
copies of the ATM gene, have a wide variety of mani-
festations, from neurodegeneration and immune defi-
ciency to malignancies. AT carriers as a group, who con-
stitute ∼1% of the population, have been found in some
epidemiological studies to share a specific phenotype:
increased cellular radiosensitivity and risk of cancer.
However, these differences do not reliably distinguish
individuals as carriers. In the present study, we pro-
vide evidence that the phenotype extends to differ-
ences in expression of many genes, both at baseline
and in response to low-dose IR. DNA microarrays have
been used successfully by others (Golub et al. 1999; Al-
izadeh et al. 2000; Bittner et al. 2000; Perou et al. 2000)
to classify somatic mutations in cancers; here, we dem-
onstrate their power in classifying individual carriers of
recessive germline mutations. Our results for baseline
expression levels suggest that carriers of mutations for
other autosomal recessive diseases might be identified by
the same approach.
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Table 2
Known Genes with the Largest Expression Differences between AT Carriers and Control Individuals in Post-IR
Time Course
Gene Gene Name Functiona
KLK5 Kallikrein 5 Protease
COL15A1 Collagen, type XV, alpha 1 Connective tissue development and maintenance
BCL3 B-cell CLL/lymphoma 3 Cell cycle control
NRP2 Neuropilin 2 Receptor for semaphorins
KIAA0993 Unknown
XPO1 Exportin 1 Cell cycle–regulated nuclear export
IFNAR2 Interferon receptor 2 Signal transduction
CGR19 Cell growth regulatory with ring finger domain Negative control of cell proliferation
MLF2 Myeloid leukemia factor 2 Cell growth
PLCB2 Phospholipase C, b2 Hydrolyzes phosphatidylinositol 4,5-bisphosphate
NOTE.—Genes are ranked by difference in discriminant scores.
a Determined using LocusLink of the National Center for Biotechnology Information.
The causes and pathogenesis of malignancies in AT
carriers are poorly understood. A major obstacle has
been the lack of methods for reliably identifying carriers
in the population. In our analysis of baseline gene ex-
pression, we found significantly more genes than ex-
pected by chance (71 vs. 27) that differed between lym-
phoblastoid cell lines from AT carriers and from control
individuals. The expression levels of these genes indi-
vidually are not very different between AT carriers and
control individuals. This is not surprising, since the dif-
ferences between AT carriers and control individuals are
subtle. However, when the genes are considered in ag-
gregate, their expression levels are significantly different
( ) between AT carriers and control individuals.P  .005
The existing evidence that AT carriers have elevated risk
for breast cancer comes only from epidemiological stud-
ies, since AT carriers cannot be identified individually
by available diagnostic tests or physical examinations.
Here, we showed that most of the discrimination be-
tween our present samples of AT carriers and control
individuals could be achieved using just four (LIM,
CDKN2D, TFRC, and ARF6) of the 71 genes.
For future studies, we do not propose that expression
levels of these four genes alone will allow reliable clas-
sification of all AT carriers, since our results are based
on small samples. However, to the extent that our results
are representative, the baseline expression levels of a
small number of the genes will allow the identification
of the majority of carriers of the ATM mutations. The
present results are based on relatively small samples of
carriers and control individuals. For this reason, and
because of the known heterogeneity of AT mutations,
the present study will need to be replicated to identify
the set of genes that consistently provide discrimination.
It will also be necessary to determine the accuracy of
our expression assay in identifying AT carriers in the
general population, where the frequency of AT carriers
is much lower and where there are carriers of syndromes
similar to AT. As a practical matter, it will be necessary
to extend results to peripheral blood lymphocytes so that
the expression assays can be performed using blood sam-
ples, thereby eliminating the need to prepare cell lines.
We designed our study to identify genes that account
for the differences between AT carriers and control in-
dividuals in cellular response to IR. We identified 183
cDNA clones (101 ESTs and 82 known genes) that differ
between AT carriers and control individuals in expres-
sion patterns over five time points after IR. A complete
biological explanation will require functional analysis
of these genes, which will help to explain why AT car-
riers are at increased risk of malignancies.
Cellular assays have shown that cells from AT car-
riers, unlike control cells, have incomplete cell cycle ar-
rest in response to IR (West et al. 1995; Xu and Bal-
timore 1996; Barlow et al. 1999). Our data agree with
this finding. Among the genes that have different ex-
pression patterns between the two cell types at baseline
and in response to IR are several that play a role in
proliferation, apoptosis, and cell cycle regulation. In the
baseline study, we found that cyclin-dependent kinase
inhibitor (CDKN2D), which regulates G1-to-S transi-
tion by controlling the phosphorylation of RB1, and
WEE1, which regulates G2-to-M transition, were both
decreased in AT carriers relative to control individuals.
This finding suggests that AT carriers may be less ef-
fective in regulation of the cell cycle at various check-
points when compared with control individuals. In the
IR study, the expression level of exportin 1, which me-
diates nuclear export of cyclin B, is up-regulated in con-
trol cells in response to IR, compared with cells from
AT carriers. In addition, several genes involved in DNA
repair, such as BRCA2, are up-regulated in control cells,
compared with AT carriers. This also supports the ob-
servation that cells from AT carriers are less efficient
when compared with cells from control individuals in
response to IR-induced DNA damage. ATM protein is
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a protein tyrosine kinase involved in early steps of re-
sponse to DNA damage. Thus it is perhaps not sur-
prising to find that mutations in one copy of the ATM
gene can cause a plethora of changes in the genes down-
stream of ATM—with many of them being involved in
the regulation of cell proliferation and cell death.
Since carriers of recessive diseases are usually several
hundred times more common than affected patients,
there is considerable practical significance in under-
standing how they differ from control individuals. This
point is illustrated with AT. Clinically, it is important
to develop methods for identifying AT carriers and to
understand their radiosensitivity. Previous studies have
indicated that IR used in diagnosis and treatment may
trigger the development of cancer in AT carriers (Swift
et al. 1986, 1991; Athma et al. 1996; Broeks et al.
2000). The dose of IR (3 Gy) used in the present study
is relatively low. As a point for comparison, the max-
imum permissible exposure for IR workers is 5 Gy per
year. Thus the differences detected in expression of rel-
evant genes are not the result of unusually high levels
of IR. This observation reinforces the need to take a
more active role in identifying AT carriers, to minimize
their risk of developing radiation-induced cancers. The
use of expression analysis, to identify carriers of other
recessive diseases and to improve understanding of their
phenotype, is likely to have correspondingly extensive
implications.
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